| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Fin. & Admin Officer | Sr. VP, Finance & Admin. & CFO | Treasurer and CFO
1 company
Paul J Mellett last filed a Form 4 in February 2025, as Chief Fin. & Admin Officer at ENTA. Paul J Mellett's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Paul J Mellett a middling insider score of 63/100, based on 4 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +18.3%.
At the last filing, the largest reported position was 95,884 shares of ENTA. The ENTA filings lean toward selling, a net 132,443 shares.
Paul J Mellett has 52 Form 4 filings on record from January 2015 to February 2025, all as Chief Fin. & Admin Officer at Enanta Pharmaceuticals (ENTA), 2015–2025.
The 90 reported transactions were 33 open-market sales, 16 stock awards, 15 option or other derivative awards and 14 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 16 sales worth about $7.2M.
The largest open-market sale was 15,000 shares of ENTA at an average $120.57 on June 11, 2018, about $1.8M.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 6, 2024 | ENTA Enanta Pharmaceuticals Inc | Chief Fin. & Admin Officer | Sell10b5-1 | 2,591 | $8.06 | $20,883.46 | -2.7% | -10.3% | +82.5% | |
| Dec 5, 2023 | ENTA Enanta Pharmaceuticals Inc | Sr. VP, Finance & Admin. & CFO | Sell | 2,412 | $9.63 | $23,227.56 | -2.5% | +65.3% | -9.9% | |
| Mar 15, 2023 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sale+OE | 10,440 | $44.43 | $463,802.20 | -9.7% | -44.3% | -68.9% | |
| Feb 9, 2023 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sell | 5,000 | $53.76 | $268,816.00 | -5.7% | -50.0% | -76.7% | |
| Jan 8, 2021 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sell | 6,000 | $45.58 | $273,462.60 | -8.9% | - | - | |
| Jan 2, 2020 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sale+OE | 10,000 | $60.88 | $608,799.59 | -20.0% | - | - | |
| Jun 11, 2018 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sell | 15,000 | $120.57 | $1,808,523.06 | -17.0% | - | - | |
| Mar 19, 2018 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sell | 9,000 | $86.48 | $778,330.51 | -9.2% | - | - | |
| Nov 24, 2015 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sell | 6,000 | $30.15 | $180,921.71 | -9.9% | - | - | |
| Oct 15, 2015 | ENTA Enanta Pharmaceuticals Inc | Treasurer and CFO | Sell | 7,500 | $40.10 | $300,742.50 | -11.0% | - | - |